AI Article Synopsis
- - Asthma is a widespread inflammatory disease requiring new treatment options to improve patient quality of life.
- - Research highlights various promising therapeutic targets, particularly interleukins and their receptors, for developing new asthma drugs.
- - Both small molecules and large molecule antibodies are being explored as potential new treatments, with hopes they will be approved for use to benefit asthma patients.
Article Abstract
Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary to search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of literature of new therapeutic targets, there are various targets and drugs reported to be promising for the treatment of asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also their receptors. Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. Therefore, through this research, we can see advances in the search for new targets and promising drugs to treat asthma. It is expected that these new drug candidates will eventually be approved and marketed so that asthma patients can use them to enhance their quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389557517666170927145011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!